Evidence map›Paper›PMID 37910527›Full record

ArticlePloS one2023

Clinical and laboratory features of COVID-19 illness and outcomes in immunocompromised individuals during the first pandemic wave in Sydney, Australia.

Nila J Dharan, Sarah C Sasson, Golo Ahlenstiel, Christopher R Andersen, Mark Bloch, Griselda Buckland, Nada Hamad, Win Min Han, Anthony D Kelleher, Georgina V Long and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Nila J DharanKirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.ORCID 0000-0003-1175-5962
Sarah C SassonKirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.
Golo AhlenstielBlacktown Hospital, Blacktown, New South Wales, Australia.ORCID 0000-0003-0026-1457
Christopher R AndersenRoyal North Shore Hospital, St Leonards, New South Wales, Australia.
Mark BlochKirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.
Griselda BucklandKirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.
Nada HamadSt Vincent's Hospital, Darlinghurst, New South Wales, Australia.
Win Min HanKirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.ORCID 0000-0003-3731-7960
Anthony D KelleherKirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.
Georgina V LongRoyal North Shore Hospital, St Leonards, New South Wales, Australia.ORCID 0000-0001-8894-3545
Gail V MatthewsKirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.
Michael M MinaNorthern Beaches Hospital, Frenchs Forest, New South Wales, Australia.
Emmanuelle PapotKirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.
Kathy PetoumenosKirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.
Sanjay SwaminathanWestmead Hospital, Westmead, New South Wales, Australia.
Barbara WithersSt Vincent's Hospital, Darlinghurst, New South Wales, Australia.
James YunSchool of Medicine, Sydney, University of Notre Dame, Chippendale, New South Wales, Australia.
Mark N PolizzottoKirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.
CORIA Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

People with immunocompromising conditions are at increased risk of SARS-CoV-2 infection and mortality, however early in the pandemic it was challenging to collate data on this heterogenous population. We conducted a registry study of immunocompromised individuals with polymerase chain reaction (PCR)-confirmed SARS-CoV-2 infection from March-October 2020 in Sydney, Australia to understand clinical and laboratory outcomes in this population prior to the emergence of the Delta variant. 27 participants were enrolled into the study including people with a haematologic oncologic conditions (n = 12), secondary immunosuppression (N = 8) and those with primary or acquired immunodeficiency (i.e. HIV; N = 7). All participants had symptomatic COVID-19 with the most common features being cough (64%), fever (52%) and headache (40%). Five patients demonstrated delayed SARS-CoV-2 clearance lasting three weeks to three months. The mortality rate in this study was 7% compared to 1.3% in the state of New South Wales Australia during the same period. This study provides data from the first eight months of the pandemic on COVID-19 outcomes in at-risk patient groups.

Indexed as

COVID-19AustraliaHumansPandemicsSARS-CoV-2

Identifiers

PMID37910527
PMCPMC10619805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.